Additionally, this methodology may also be applied to ICI-resistant tumors with low CD8+ T cell levels, despite high initial PD-L1 expression patterns, because MacTriggers can also infiltrate PD-1-positive CD8+ T cells into tumor tissues. This evidence concerns the gene CD8A and neoplasm.